Format

Send to

Choose Destination
BMC Cancer. 2019 Sep 6;19(1):890. doi: 10.1186/s12885-019-6114-2.

Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.

Author information

1
Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Idaigaoka 1-1, Hasama, Yufu City, Oita, 879-5593, Japan. ktanaka@oita-u.ac.jp.
2
JCOG Data Center, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
3
Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, 541-8567, Japan.
4
Department of Orthopaedic Surgery, National Cancer Center, Tokyo, 104-0045, Japan.
5
Department of Orthopaedic Surgery, Shizuoka Cancer Center, Shizuoka, 411-0934, Japan.
6
Department of Orthopaedic Surgery, Kanagawa Cancer Center, Kanagawa, 241-0815, Japan.
7
Department of Orthopaedic Surgery, Kyushu University, Fukuoka, 812-8582, Japan.
8
Department of Orthopaedic Surgery, Kanazawa University, Ishikawa, 920-8641, Japan.
9
Department of Orthopaedic Surgery, Keio University, Tokyo, 160-0016, Japan.
10
Department of Orthopaedic Surgery, Niigata Cancer Center Hospital, Niigata, 951-8133, Japan.
11
Department of Orthopaedic Surgery, Sapporo Medical University, Sapporo, 060-8556, Japan.
12
Department of Orthopaedic Surgery, Tohoku University, Sendai, 980-8575, Japan.
13
Department of Orthopaedic Surgery, Nihon University, Tokyo, 173-8610, Japan.
14
Department of Orthopaedic Surgery, Kyoto University, Kyoto, 606-8501, Japan.
15
Department of Orthopaedic Surgery, Teikyo University, Tokyo, 173-8606, Japan.
16
Department of Orthopaedic Surgery, Mie University, Mie, 514-8507, Japan.
17
Department of Orthopaedic Surgery, National Kyushu Cancer Center, Fukuoka, 811-1395, Japan.
18
Department of Orthopaedic Surgery, Hokkaido Cancer Center, Sapporo, 003-0804, Japan.
19
Department of Orthopaedic Surgery, Chiba Cancer Center, Chiba, 260-8717, Japan.
20
Department of Orthopaedic Surgery, Kyorin University, Tokyo, 181-8611, Japan.
21
Department of Orthopaedic Surgery, Cancer Institute Hospital, Tokyo, 135-8550, Japan.
22
Department of Orthopaedic Surgery, Gifu University, Gifu, 501-1194, Japan.
23
Department of Orthopaedic Surgery, Osaka University, Osaka, 565-0871, Japan.
24
Department of Orthopaedic Surgery, Okayama University, Okayama, 700-0914, Japan.
25
Kyushu Rosai Hospital, Kitakyushu, 800-0296, Japan.

Abstract

BACKGROUND:

Soft-tissue sarcomas (STS) are rare malignant tumors those are resistant to chemotherapy. We have previously reported the 3-year follow-up result on the efficacy of perioperative chemotherapy with doxorubicin (DXR) and ifosfamide (IFM) for high-risk STS of the extremities (JCOG0304). In the present study, we analyzed the 10-year follow-up results of JCOG0304.

METHODS:

Patients with operable, high-risk STS (T2bN0M0, AJCC 6th edition) of the extremities were treated with 3 courses of preoperative and 2 courses of postoperative chemotherapy, which consisted of 60 mg/m2 of DXR plus 10 g/m2 of IFM over a 3-week interval. The primary study endpoint was progression-free survival (PFS) estimated by Kaplan-Meier methods. Prognostic factors were evaluated by univariable and multivariable Cox proportional hazards model.

RESULTS:

A total of 72 patients were enrolled between March 2004 and September 2008, with 70 of these patients being eligible. The median follow-up period was 10.0 years for all eligible patients. Local recurrence and distant metastasis were observed in 5 and 19 patients, respectively. The 10-year PFS was 65.7% (95% CI: 53.4-75.5%) with no PFS events being detected during the last 5 years of follow-up. The 10-year overall survival was 78.1% (95% CI: 66.3-86.2%). Secondary malignancy was detected in 6 patients. The subgroup analysis demonstrated that there was significant difference in survival with regard to primary tumor size.

CONCLUSIONS:

Only a few long-term results of clinical trials for perioperative chemotherapy treatment of STS have been reported. Our results demonstrate that the 10-year outcome of JCOG0304 for patients with operable, high-risk STS of the extremities was stable and remained favorable during the last 5 years of follow-up.

TRIAL REGISTRATION:

This trial was registered at the UMIN Clinical Trials Registry as C000000096 on August 30, 2005.

KEYWORDS:

10-year follow-up; Doxorubicin and ifosfamide; Extremity; Perioperative chemotherapy; Soft tissue sarcoma; Survival

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center